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ABSTRACT
y-Aminobutyric Acid Inhibits Synergistic Interleukin-6 Release but not 
Transcriptional Activation in Astrocytoma
By
Joseph Dana Roach Jr.
Dr. Bryan L. Spangelo, Examination Committee Chair 
Professor of Chemistry 
University of Nevada, Las Vegas
A decline in the inhibitory neurotransmitter y-aminobutyric acid (GABA) may 
enhance cytokine release in Alzheimer’s disease (AD) resulting in 
neuroinflammation. We investigated the GABA-mediated suppression of the 
synergistic release of interleukin-6 (IL-6) due to interleukin 1-p (IL-1p ) and tumor 
necrosis factor a  (TNF-a) synergy. Our results indicate that p38 and nuclear 
factor (NF)-kB are essential for the synergistic release of IL-6 by IL-ip and TNF- 
a. Both IL-ip and TNF-a stimulate p38 phosphorylation and each are able to 
enhance the degradation of the NF-kB inhibitor, IxB-a, with no change in IxB-p. 
Interestingly, co-treatments IL-ip and TNF-a induce a greater increase in IxB-a 
degradation compared to either cytokine alone. In addition, co-treatment 
increased IL-6 mRNA indicating synergy on a transcriptional level. In addition, 
Western blot analysis revealed that co-treatments of IL-ip and TNF-a resulted in 
an increase of IL-6 protein that can be reversed by GABA. Furthermore, co­
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treatments of IL-ip and TNF-a resulted in activation of p38 and degradation of 
kB -a at earlier time points compared to either cytokine alone. These data 
suggests that IL-ip and TNF-a synergizes by accelerating p38 and NF-kB 
activation, increasing IL-6 transcription. Although GABA suppressed the IL-ip 
and TNF-a synergistic release of IL-6, it did not affect kB -a or kB-p 
degradation, p38 phosphorylation or IL-6 transcription. Instead it appears that 
GABA may inhibit IL-6 translation. We have demonstrated that this synergistic 
release of IL-6 can be inhibited by GABA and its receptor agonists.
IV
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CHAPTER 1
INTRODUCTION 
The biological foundation of the central nervous system 
In order to understand the effects of Alzheimer disease it is essential to 
discuss the biological foundations of the central nervous system. The central 
nervous system (CNS) consists of several cell types, including neurons 
responsible for information processing and transmission. Neurons are aided by 
supporting cells referred to glial cells. Nerve cells are secretory cells of varying 
morphologies capable of information transfer thus generating electrochemical 
impulses that travel the length reaching the synaptic cleft (Bowsher, 1988).
Nerve cells have the typical cellular features as well as other adaptations and 
sacrifices to suit their unique roles. For example, neuronal cells can be relatively 
large and long when compared to the morphology of other types of cells and form 
vast networks to undertake information transfer. This large size and length is 
essential in establishing communication networks with other cells in different 
parts of the body. Each neuron consists of the main cell body containing the 
nucleus and NissI bodies which are large congregations of ribosomes (Bowsher, 
1988), which are indicative of a higher than normal protein production.
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Another notable adaptation of neuronal cells is that they are less tolerant to 
metabolic changes. For neurons, immediate cell death can occur if the oxygen 
supply and other substances are diminished which gives neurons the 
characteristics of a simple metabolic profile (Bowsher, 1988). Another adaptation 
is that neuronal cells consume energy at a higher rate than most other cells. To 
meet this energy demand mitochondria take up nearly 66% of the entire volume 
of a neuron (Bowsher, 1988). Yet another biological adaptation includes the 
inability to replicate. The cell must sacrifice replication because of its size and 
due branches that extend to varying distances and can range from a few 
millimeters to over a meter in length (Bowsher, 1988). These dendritic trees are 
essential in forming communication networks with other cells. In addition, 
considerable time and resources are used to establish these connections that 
can be lost if the cell were to undergo morphological changes during mitosis. 
These branching bodies that extend from the neuronal main cellular body are 
called dendrites and axons, which function to receive and transmit information, 
respectively.
Dendrites receive information transmitted from other cells and conduct this 
information towards the cell body and even to the axon or nerve fiber (Lawson, 
2003). The ends of axons transmit and communicate to other cells (Lawson, 
2003). Along these axons are microtubule (referred to as neurofilaments or 
neurotubules) networks which extend to the terminals where neurotransmission 
occurs (Bowsher, 1988). It is along these tubules that the phenomenon known as 
axonal transport occurs, which is the active movement of neurotransmitters
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and/or their precursors along the axon in either direction (Bowsher, 1988). One 
can think of these filaments as a highway for substances to be shuttled to and 
from the axonal terminal, referred to as the bouton (button).
It is at the bouton where neurotransmission occurs through direct contact to 
another cell body or to the dendrites of another cell (Bowsher, 1988). Electron 
microscopy has shown that the bouton contain a large array of synaptic vesicles. 
A nervous impulse travels along the axon and arrives at the bouton, resulting in 
the release of neurotransmitters from the vesicles into the synaptic cleft 
(Bowsher, 1988).
Biochemical features of Alzheimer disease
Alzheimer disease (AD) is a debilitating disease that affects the CNS. It was 
first described by the German physician Alois Alzheimer in 1907 (Alzheimer, 
1907) and despite the fact that researchers have had approximately one hundred 
years to study this disease the cause is still unknown (Griffin, 2006) and no cures 
have been developed. It is the most common form of dementia in the elderly. In 
the U.S. alone AD to affects 4.5 million people and this is expected to increase to
13.2 million by 2050 (Herbert et al., 2003). In addition it has been estimated that
24.3 million people worldwide are affected by AD and this number is expected to 
double every 20 years as life expectancy increases (Ferri et al., 2005). On the 
biological level there are three features that define Alzheimer pathology. These 
are [1] senile plaque formation; [2] neurofibrillary tangles or paired helical 
filaments (PHF) first observed and characterized by Dr. Alzheimer in 1907; and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
[3] inflammation processes which contribute to the deposition of amyloid plaques 
that form senile plaques (Qiao et al., 2001).
The amyloid plaques (A|3), originate from the processing of amyloid precursor 
protein (APP) (Kang et al., 1987). Though the exact function or purpose of APP 
or amyloid plaques is unknown, there is much data demonstrating potential roles 
for APP. APP has a structure similar to membrane bound proteins (Kang et al.,
1987), indicative of some unknown function localized to cell membranes. 
Furthermore, APP is highly expressed in nen/e terminals and may be essential 
for synaptic formation during brain development, neurogenesis and 
neuroregeneration (Loffler and Huber, 1982 Chen et al., 2006, and Selkoe et al.,
1988). It is interesting to note that APP is up-regulated after head injury 
(Gentlemen et al., 1993) and that APP is also deposited in aged Down syndrome 
patients (trisomy-21); (Kang et al., 1987). Furthermore, it is also interesting to 
note that the APP gene is located on chromosome 21 (Selkoe et al., 1988) and 
that individuals affected with trisomy-21 have an earlier onset of brain growth 
arrest, brain atrophy and the development of AD (Wisniewski et al., 1985). Using 
trisomy-21 as a model, these observations suggests that up-regulation of APP 
expression and processing can lead to the progression of AD.
The formation of amyloid plaques occurs through the processing of APP 
fragments which are cleaved by a family of enzymes known as secretases . APP 
processing results in the formation of P-amyloid (Ap) peptide fragments of ~ 39- 
43 amino acid residues in length (Buxbaum et al., 1998, Cintron et al., 1994 and 
Selkoe et al., 1996), each of which are found in amyloid plaque deposits in AD
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patients. In addition, missense mutations occur more frequently in the PAPP 
gene of aged individuals resulting in the formation of extremely hydrophobic, 
amyloidogenic and insoluble fragments (Cintron et al., 1994) which can further 
exacerbate AD. These Ap fragments are proposed to be the underlying force that 
ultimately initiates and drives AD development and progression (Hardy and 
Higgins 1992).
This idea that Ap plaque formation is the causative force of AD has become 
known as the amyloid cascade hypothesis (Hardy and Higgins, 1992). This 
hypothesis is widely acknowledged by mainstream AD researchers but is not 
entirely accepted. For instance, it has been reported that there is a little or no 
correlation between Ap plaque deposition and neurological dysfunction (Terry et 
al., 1999-2000 and Klein et al., 2001). Terry et al., argue that it is the loss of the 
synaptic terminals, rather than amyloid plaque deposition, which leads to the 
development and progression of dementia. Those who do not agree with the 
amyloid cascade hypothesis are few as there are over 5000 publications (Klein et 
al., 2001) that support the hypothesis.
The second hallmark feature of AD is neurofibrillary tangles. Along the 
lengths of the axons are microtubule fibers forming the backbone of the 
axoplasmic transport system. These tubules serve as the internal support 
structures transporting nutrients, vesicles, mitochondria, and other substrates 
from the cell body to the ends of the axon and back (Griffin, 2006). A low 
molecular weight protein known as tau is an integral component of microtubules 
and can bind directly to the microtubule fiber promoting microtubule assembly
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(Avila 2006 Caceres et al., 1990 and Drubin et al., 1986). In AD, tau can become 
hyper-phosphorylated allowing it to bind together and form tangles (Braak et al., 
1994) which have become known as paired helical filaments (PHFs) or 
neurofibrillary tangles (NFTs). In addition, tau can impede axoplasmic transport 
by competitive binding with the motor protein kinesin (Ebneth et al., 1998, Stamer 
et al., 2002 and Trinczek et al., 1999). Another negative effect of tau hyper­
phosphorylation is increased resistance to protein degradation (Poppek et al., 
2006), blocking axoplasmic transport and stabilizing PHFs.
The third feature of AD affected tissues is neuroinflammation. The microglia 
which support neurons perceive amyloid plaques as foreign inclusions and 
initiate a inflammatory response to remove these depositions by phagocytosis 
(Dewitt et al., 1998). Initiation of the inflammatory response causes activation of 
glial cells resulting in the release of pro-inflammatory cytokines such as IL-1 (3 and 
SIOOP, both of which have been associated with senile plaque formation 
(Griffin, 2006). In addition, the release of inflammatory cytokines such as IL-ip 
can up-regulate the expression and processing of APP leading to the deposition 
of additional Ap fragments (Goldgaber et al., 1989 and Buxbaum et al., 1992). As 
more APP is processed and Ap deposition increases, the microglia cells 
eventually become overburdened in an attempt to remove plaques Storing these 
fragments within the glia cell forces the cell to undergo lysis releasing the Ap 
fragments that had been removed (Nagele et al., 2004). This system may self 
propagate and amplify itself promoting the development and progression of AD 
through an inflammatory response.
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IL-ip can lead to the phosphorylation of tau, which demonstrates a possible 
relationship between IL-1 p, tau and the formation of neurofibrillary tangles. Li and 
colleagues have reported that an increase in IL-ip correlated with the increased 
phosphorylation of tau, which in turn decreased synaptophysin synthesis (Li et 
al., 2003). They also reported that this effect can be blocked using the p38 
inhibitor SB203580. They concluded that IL-ip signaling is mediated through p38 
and is involved in tau phosphorylation, potentially leading to neurofibrillary 
tangles (Figure 1).
Mitogen-activated protein kinases 
The MAPK superfamily of kinases plays a major role in cellular signaling of 
many different cellular processes. The MAPK family includes p38, extracellular- 
signal regulating kinase (ERK) and c-Jun N-terminal kinase (JNK). As shown 
earlier, there are data supporting p38 in pro-inflammatory and stress responses 
(Xia et al., 1995). Indirect evidence suggests that JNK may also play a role in 
inflammation (Ip and Davis 1998 and Eynott et al., 2003). In contrast ERK has an 
opposing role to that of JNK and p38 as it has been implicated in proliferation 
and cell survival (Xia et al., 1995 and Rescigno et al., 1998).
Increased activities of p38 and JNK have been implicated in a rodent model 
of AD (Savage et al., 2002) and post mortem analysis of human AD affected 
brain tissues show activated c-Jun in neurofibrillary tangles implying a role for 
JNK in AD (Pearson et al., 2006). It is interesting to note that Savage and 
colleagues reported that the pro-inflammatory and stress responsive kinases p38
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and JNK were activated in a mouse model of AD whereas the developmental and 
cell survival responsive ERK was not. From these data one can see further 
evidence of the link between inflammation and AD and the potential involvement 
of JNK. One could also argue that it is a combination of the pro-inflammatory and 
stress response of p38 and JNK, respectively, in combination with the breakdown 
of cell survival signaling of ERK that may allow the development and progression 
of AD.
Cytokines and their biological effects
Cytokines are proteins that play roles in differentiation, proliferation, 
inflammation, apoptosis, and induction of various proteins. Some cytokines 
include interleukins (IL) and tumor necrosis factors (TNF) which carry out a broad 
range of different functions in the cell. There are 33 known types of interleukins 
designated interleukins, 1-33. Interleukin-1 p (IL-ip) is an important signaling 
molecule in the pro-inflammatory response and has even been linked to AD 
(Griffin, 2006).
The IL-1 subfamily of cytokines consists of three members: IL-1 a, IL-ip and 
their negative feedback inhibitor IL-1 inhibitor (IL-li) which was later renamed to 
IL-1 receptor antagonist (IL-1 Ra) (Dinarello, 1994). The precursor of IL-1 is a 35- 
kilodalton (kDa) inactive peptide that must be processed to a 17 kDa active 
polypeptide (Hazuda et al., 1990), which can be further altered via glycosylation. 
This biologically active form binds to an IL-1 cell receptor initiating a pro- 
inflammatory response which activates the MAPK p38 and the transcription
8
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factor NF-kB (O’Niell, 2000). It is interesting to note that both p38 and NF-kB 
have been associated with inflammatory response leading to the production and 
secretion of IL-6 (Craig et al., 2000).
Another inflammatory cytokine which seems to play a role in AD is a family of 
cytokines collectively referred to as tumor necrosis factors (TNF). The first TNF 
was originally detected and observed over thirty years ago as a cell free cytotoxic 
substance that induced apoptosis in tumor cells (Granger et al., 1969). Probably 
the most characterized member of this family is TNF-a, first isolated by Carswell 
and colleagues in 1975. In addition to inducing apoptosis, TNFs have been linked 
to inflammation, host defenses, autoimmunity and other immunological 
responses (Locksley et al., 2001). Although TNF triggers beneficial 
immunological responses, some of its effects are injurious to the host organism. 
These detrimental effects include septic shock, cachexia and disease symptoms 
(Tracey and Cerami 1994).
One can postulate that IL-ip and TNF-a may initiate an inflammatory 
response through the activation of p38 and NF-kB, resulting in the production 
and release of IL-6. Inflammation contributes to the processing and release of Ap 
fragments (Goldgaber et al., 1989 and Buxbaum et al., 1992). Li and colleagues 
reported that hyperphosphorylation is caused by p38. As for NF-kB, it is 
proposed by O’Niell and colleagues that IL-ip activates p38, which in turn 
activates NF-kB resulting in IL-6 transcription. It has also been demonstrated 
that activation of NF-kB can be reversed or inhibited by p38 inhibitor SKF (Kaur 
et al., 2003). These data provides evidence that p38 inhibitors and potentially
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anti-inflammatory agents may reverse or infiibit inflammation which in turn may 
alleviate some effects of AD.
Nuclear Factor-KB
Nuclear Factor-KB (NF-kB) is a transcription factor related to the Rel family 
proteins (Ghosh et al., 1998) and exists in virtually all cell types. It is found in the 
cytoplasm bound to an intrinsic inhibitor kB (IkB) which prevents it from migrating 
to the nucleus of the cell. The activity of NF-kB can be summed up in three 
steps: [a] the inhibitor is phosphorylated by IkB kinases (IKK); [b] ubiquination 
marks it for degradation by proteosomes; and [c] released NF-kB translocates to 
the nucleus and binds to the kB binding sites located in the promoters and 
enhancers of many genes (Ghosh et al., 1998 and Abraham 2000). Some genes 
that become activated include IL-1, IL-6, TNF-a, lymphotoxins and Interferons 
(IFN). Furthermore these molecules can activate NF-kB (Kopp & Ghosh 1999) 
allowing them to prime the inflammatory response or further exacerbate it. The 
nature of the genes that are activated suggests that NF-kB is responsible for 
initiating inflammation and plays a major role in immune response (Kopp & 
Ghosh 1999).
The IkB family of NF-kB inhibitors include kB-a, kB-p, IkB-e and kB-y 
(Ghosh et al., 1998). Though inhibitors, their effects vary depending on the 
source of induction. For example, the first inhibitor to be characterized and 
cloned was kB-a (Davis et al., 1991), which regulates NF-kB through a rapid 
transient induction activity that also regulates itself in a negative feedback loop
10
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fashion where activated NF-kB causes the up-regulation of IkB-o transcription 
resulting in a bi-phasic activation period (Ghosh et al., 1998).
Where IkB-o degradation leads to transient activation of NF-kB, degradation 
of IkB-P leads to a persistent activation of NF-kB. First purified, cloned and 
characterized in 1995 its activity is much different than that of IkB-o. The 
inhibitory effect of IkB-o relies on activated NF-kB to promote the transcription of 
additional kB-a, where as activated NF-kB does not promote kB-p transcription. 
The lack of this autoregulatory feedback loop leads to the persistent activation of 
NF-kB (Thompson et al., 1995). One can speculate that the chronic inflammation 
associated with AD may be a result of the persistent activation of NF-kB rather 
than kB-p.
The last two members, kB-s and kB-y are the more recently discovered 
members. Currently, IkB-e and its functional relationship with NF-kB is still 
unknown (Spiecker et al., 2000). All members of this family of inhibitors have 
nuclear import and export functions and it has been postulated that each member 
possesses this ability to varying degrees (Lee and Hannink 2002). There is 
evidence suggesting that kB-e is less efficient in nuclear importing but is very 
effective in NF-kB export from the nucleus (Lee and Hannink 2002, Tam and Sen 
2001). Although nucleocytoplasmic shuttling abilities of kB-e has not been 
examined in detail (Lee and Hannink 2002), this proposed function is gaining in 
popularity. The last member, kB-y has been better characterized than kB-e. 
There is much experimental data suggesting that kB-y inhibits NF-kB by
11
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attaching directly to nucleotides and thus preventing NF-kB from binding to DNA 
(Bell et al., 1996). In addition, one can measure NF-kB activation indirectly by 
measuring the degradation of the different IkB inhibitors.
y-Aminobutyric acid an inhibitory neurotransmitter 
y-Aminobutyric Acid (GABA) is probably one of the most important 
neurotransmitter in the CNS (Figure 2). It is capable of mediating membrane 
hyperpolarization or depolarization and is believed to be responsible for 
developmental neuronal migration (Han et al., 2002) and rapidly inhibits synaptic 
transmission (Kolaj et al., 2004 and Otis and Mody 1992). It has even been 
shown that a GABA can inhibit the proinflammatory responses in T-cells (Tian et 
al., 2004) and inhibit IL-ip induced IL-6 release (Spangelo et al., 2004). 
Interestingly, individuals affected by AD have lower levels of GABA (Bareggi et 
al., 1982); however, these findings are in constant debate as there are many 
reports that support strong, little or no correlations of AD and GABA levels.
Receptors of GABA are functionally subdivided as GABAa or GABAb 
receptors. The ionotropic GABAa receptor conducts chloride ions (Olsen and 
Tobin 1990) and mediates fast inhibitory responses (Banks et al., 2002). GABAa 
receptors are hetero-oligomeric protein structures that are composed of 
pentamers each approximately 50 kDa (Olsen and Tobin 1990). In addition, it is 
possible to selectively activate the GABAa receptor through the use of muscimol 
(Figure 3; Murashita el al., 2007) or isoguvacine oxide (Frolund et al., 1995).
12
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In contrast to the ionotropic GABAa receptor the GABAb is a metabotropic G 
protein coupled receptor (Kerr and Ong 2001). GABAa illicits fast inhibitory 
responses, GABAb is responsible for slower inhibitory responses (Tamas et ai., 
2003 and Federici et al., 2005). Activation of GABAb receptors results in the 
reduction of neurotransmission at excitatory and inhibitory synapses through an 
increase in potassium conductance or a decrease in calcium currents (Kerr and 
Ong 2001). One can selectively activate the GABAb receptor with the use of the 
drug baclofen, structure shown in (Figure 3; Bartoletti et al., 2004).
Hypothesis Statement 
Previous unpublished results demonstrated that GABA inhibits the release of 
IL-6 due to TNF-a and IL-ip and these results were latter confirmed (Figure 4). 
In addition, our preliminary results suggest that GABA inhibits IL-6 release and 
may not be through a decrease in p38 activation or an inhibition of NF-kB 
activation. In respect to the role played by inflammatory cytokines in AD, the work 
presented in this thesis come from three separate but related hypothesis 
statements. Hypothesis I: the synergistic effect of TNF-a and IL-ip arises from 
an increase in IL-6 transcription. Hypothesis II: GABA, affects p38 or NF-kB 
activation. Hypothesis III: GABA may also inhibit the release of the pro-
inflammatory cytokine IL-6 by preventing its transcription induced by TNF-a and 
IL-ip.
13
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CHAPTER 2
MATERIALS AND METHODS 
Chemicals, reagents and equipment 
y-Amino butyric acid (GABA), glycine, sodium chloride (NaCI), potassium 
chloride, 4-(2-hydroxyethyl)-monosodium salt (HEPES), sodium dodecyl sulphate 
(SDS), tris-(hydroxylmethyl)-amino-methane (Tris), tris-(hydroxylmethyl)-amino- 
methane hydrochloride, Tween-20, dimethyl sulfoxide (DMSG), 2- 
mercaptoethanol (P-ME), muscimol, baclofen and bromophenol blue were 
obtained from Sigma-Aldrich (St. Louis, MO) and were of the highest grade 
possible. High-molecular weight poly-D-lysine (PDL) hydrobromide was obtained 
from BD Biosciences (Bedford, MA). The pre-stained protein ladder was 
obtained from Bio-Rad (Hercules, CA). Roswell Park Memorial Institute (RPMI)- 
1640, PSN antibiotic mix, trypsin- ethylenediaminetetraacetic acid (EDTA), heat- 
inactivated fetal bovine serum (FBS), phosphate-buffered saline (PBS pH 7.2), 
PureLink Micro-to-Midi® total RNA purification system. Superscript II reverse 
transcriptase and trypan blue were obtained from Invitrogen (Carlsbad, CA). 
Methanol was obtained from EMD Chemicals (Gibbstown, NJ). Bovine serum 
albumin (BSA) was obtained from Gemini Bioproducts (Woodland, CA). 
Recombinant rat IL-ip, TNF-a and rabbit anti-rat IL-6 antibody were obtained
14
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from PeproTech Inc. (Rocky Hill, NJ). Rabbit anti-rat kB-a, kB-p, 
phosphorylated p38 (T180/Y182), total p38, total JNK, mouse anti-rat 
phosphorylated JNK (T183/Y185), rabbit anti-rat IL-6 antibody and the 
biotinylated protein ladder was obtained from Cell Signaling (Danvers, MA). 
Goat anti-rabbit and goat anti-mouse horseradish peroxidase (MRP) conjugated 
secondary antibodies were obtained from KPL (Gaithersburg, MD). Bay 11-7082, 
were obtained from EMD Biosciences (La Jolla, CA). The rat 06  Glioma cell 
lines were from the American Tissue Type Culture Collection (Rockville, MD). 
Rat IL-6 sandwich enzyme-linked immunosorbent assay (ELISA) kits, M-PER®, 
precasted 12% SDS- polyacrylamide gel electrophoresis (PAGE) gels, protease 
and phosphatase inhibitor cocktails, and the microBCA® protein assay kit were 
all obtained from Pierce Biotechnology (Rockford, IL). Hoefer SE 260 mini­
vertical gel electrophoresis unit, EPS 2A200 power supply, Hoefer TE 22 tank 
transfer unit, MultiTemp III thermostatic circulator. Enhanced 
Chemiluminescence (ECL)-Plus® detection reagent was obtained from 
Amersham (Piscataway, NJ). Schleicher & Schuell Optitran® brand supported 
0.45 pm nitrocellulose membranes were obtained from ISC Bioexpress 
(Kaysville, UT). Rabbit anti-rat IL-6 antibody was purchased from Cell Sciences 
(Canton, MA). All small molecule inhibitors dissolved in sterile solvent, aliquoted 
and stored at -20 °C until use. The final concentrations of DMSO never exceeded 
0.1% of the final solution.
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C6 glioma cell culture 
Rat C6 glioma cells were maintained in continuous culture in a humidified 
atmosphere containing 95% air and 5% CO2 in complete medium (RPMI- 
1640/phenol red, medium containing 10% heat-inactivated PBS, 25 mM HEPES 
pH 7.4, and PSN antibiotic mix). Cells were grown either in 25 cm  ^or 75 cm  ^
area flasks. After 3-4 days in culture, cells were removed from the tissue culture 
flasks with 2 mL (for the 25 cm  ^ area flask) or 6 mL (for 75 cm  ^area flask) of 
0.25% trypsin/ 0.05% EDTA in Hanks-buffered salt solution. Trypsin was 
inactivated upon the addition of 8-24 mL of complete medium, cells were 
centrifuged, pelleted, supernatant removed, and the pelleted cells resuspended 
in complete medium. Cell suspension densities and cellular viability were 
determined via trypan blue exclusion. The cells were then placed (passed) back 
into continuous culture (1.25 x 10® cells/25 cm^-area flask, BD Falcon) or were 
seeded into tissue culture plastic-ware at the plating densities noted for 
experiments. In all experiments presented, C6 glioma cells were used between 
passages 5-35.
Cytokine quantification via ELISA 
Rat C6 glioma cells were plated (1.0 x 10®/well) on 24 well plates using poly- 
D-lysine (PDL) in complete medium and allowed to incubate 24 h to ensure 
attachment. For the experiment, cells were washed twice with 2 mL serum-free 
RPMI 1640 and incubated in serum-free RPMI-1640 in the absence or presence 
of agents for the times and doses indicated for the experiments. IL-6 release was
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then assayed via rat IL-6 ELISA (Pierce Biotechnology) according to the 
manufacturers’ instructions.
Collection of cellular protein lysates 
Rat C6 glioma cells were plated (3.0 x 10®/dish) on PDL-coated 35 x 10 mm 
dishes in complete medium, and allowed 24 h to attach. Following the 
attachment period, the cells were washed twice with 2 mL serum-free RPMI-1640 
and incubated in serum-free RPMI-1640 in the absence or presence of 
stimulation agents for the times and doses indicated for the experiments. After 
treatments cells were washed twice in 2 mL ice cold PBS, and scraped in 200 pL 
of M-PER® (Pierce) containing both phosphatase and protease inhibitors (each 
from Pierce). Protein-containing solutions were kept on ice and vortexed in 10 
minute intervals for a total time of 30 minutes on ice. Lysates were then 
centrifuged at 14,000 x gf for 10 min at 4 °C and 175 pL of the supernatant was 
recovered. Protein concentrations were determined with Micro-BCA protein 
assay kit (Pierce) using BSA as a standard and accordance to manufacturers’ 
instructions. Protein lysates were diluted by 20% using a 2X SDS-PAGE loading 
buffer (10 % w/v SDS, 2 % v/v glycerol, 0.1 % w/v bromophenol blue, 0.5 M Tris 
pH 6.8, and 5% v/v (3-ME), and boiled for 3 min. Protein lysates were 
subsequently separated by SDS-PAGE Western blot analysis and samples were 
stored at -80 °C for future analysis.
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RNA extraction and semi-quantitative RT-PCR
Rat C6 glioma cells were plated (3.0 x 10®/dish) on PDL-coated 35 x 10 mm 
dishes in complete medium, and allowed 24 h to attach. Following the 
attachment period, the cells were washed twice with 2 mL serum-free RPMI-1640 
and incubated in serum-free RPMI-1640 in the absence or presence of 
stimulation agents for the times and doses indicated for the experiments. After 
treatments cells were washed twice in 2 mL ice cold PBS. Total RNA was then 
extracted using the Invitrogen PureLink total RNA purification system.
To detect the presence of mRNA encoding IL-6 and glyceraldehydes-3- 
phosphate dehydrogenase (G3PDH), semi-quantitative RT-PCR analyses were 
performed as described by Elsawa et al., 2004 and Best et al., 1995. One pg of 
total RNA was reverse transcribed using Superscript II reverse transcriptase 
(Invitrogen), and a portion of the total cDNA was amplified by PGR using 94°C 
dénaturation, 55°G annealing and 72°C extension temperatures, for 27 
cycles with the first four cycles having extended times. Positive and negative 
strand primers used for the amplification of each mRNA species were as follows; 
G3PDH, GGAGGGAAAGGGGTGATGATGTC and
ATGGGTGTTGACGAGGTTGTTG; IL-6, AGAGTTGTGGAATGGGAATTC and 
GGTTGTGTGAGTGTAAGTTGTGGA. Amplified products were electrophoresed 
on ethidium bromide stained gels and visualized under UV illumination. Analysis 
of cDNA samples were corrected for expression of G3PDH.
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SDS-PAGE Western blot analysis
Protein lysates were separated on a SDS-PAGE gel. Poly- acrylamide gels 
were purchased precasted (Pierce). The gels were subsequently transferred to a 
Hotter SE 250 Minivertical Gel Electrophoresis Unit (Amersham) filled with Tris- 
HEPES (0.1 M HEPES, 0.1 M Tris, 0.1% w/v SDS) running buffer. Equal 
amounts of protein (5 -  25 pg) were loaded into each lane of the precast gel. 
Biotinylated and prestained protein ladders were also loaded onto the stacking 
gel to determine molecular weight mobility and transfer efficiency, respectively. 
The proteins were electrophoretically separated at 4 °C, using a constant voltage 
of 100 V. Following electrophoresis, the proteins were transferred (Hoefer TE22 
Mighty Small TransPhor Tank, Amersham) to 0.45 pm nitrocellulose membranes 
at 4 °C, using constant amperage of 360 mA, for 90 min in Western transfer 
buffer (25 mM Tris, 192 mM Glycine, and 20% v/v methanol, note: pH was not 
adjusted).
Following the transfer period, protein-containing membranes were washed 
once for 5 minutes in tris-buffered saline containing tween (TBST: 50 mM Tris pH 
7.4, 150 mM NaCI, and 0.1% v/v Tween-20) for 5 min. After the washing period 
the membranes were blocked with TBST containing 5 % nonfat milk (Nestlé 
Carnation) for 1 hour, then washed three times in 5 minutes intervals in TBST. 
The membrane was incubated 12 hours with primary antibodies at the dilutions 
indicated by manufacturer’s instructions at 4°C. After the antibody incubation 
period, the antibody solution was removed and the membranes washed in TBST 
three times for 5 minute intervals. Membranes were then incubated with a
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secondary antibody conjugated to a horseradish peroxidase (HRP) and anti­
biotin. Both secondary and anti-biotin antibodies were diluted using the 
manufactures recommendation, of 1:5000 and 1:1000, respectively. All 
antibodies were diluted in TBST containing 0.1% BSA (Antibody Dilution Buffer). 
The incubation period for secondary antibody and anti-biotin of 1 hour, 
aften/vards both were removed and washed in TBST three times for 5 minute 
intervals. Proteins were visualized on the Typhoon multipurpose imager using 
the ECL-plus® detection reagent according to the manufacturer’s specifications 
(Amersham).
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CHAPTER 3 
RESULTS
Time dependent release of IL-6 induced byTNF-a and IL-1p 
We characterized the effect of TNF-a and IL-1P on IL-6 release in a time 
dependent manner using an ELISA format. For groups treated with both 
cytokines we determined that at 4 hours no detectable amounts of IL-6 were 
release. Furthermore, we observed a time dependent release of IL-6 starting 
from 6-12 hours with an even greater amount of IL-6 release occurring at 
24hours. (Figure 5).
GABA inhibition of the synergistic release of IL-6 induced 
by TNF-a and IL-1|3 
We characterized the effect GABA on TNF-a and IL-ip induced IL-6 release 
in a time dependent manner using an ELISA format. For groups treated with both 
cytokines we observed a time dependent release of IL-6 starting from 6 hours 
onward. Furthermore, we observed that GABA inhibits the release of IL-6 at all 
time points. (Figure 6).
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Effects of GABA, muscimol, baclofen, TNF-a and IL-1(3 
on IL-6 release.
We have previously reported that GABA can inhibit the release of IL-6 
induced by IL-1 (3 treatment (Spangelo et al., 2004) using the 7TD-1 bioassay. We 
decided to re-explore these observations using an ELISA format to examine the 
effects of GABA, muscimol, baclofen, TNF-a and IL-ip on IL-6 Release (Figure 
7). In addition GABA, muscimol and baclofen were able to inhibit IL-6 release 
caused by the synergistic stimulation of both TNF-a and IL-1 p combined.
TNF-a and IL-ip Effects on p38, kB-a and kB-p 
in an extended time course 
In order to determine how TNF-a and IL-ip synergy occurs it was necessary 
to characterize the effects of TNF-a and IL-ip on p38, kB-a and kB-p. In the 
case of p38 we see that the combination of both cytokines caused the activation 
of p38 at 5 minutes with maximum activation occurring at 15 minutes followed by 
a return to basal activity at 30 minutes (Figure 8). In the case of the NF-kB 
inhibitors kB-a and kB-p we observe kB-a degradation at 5 minutes with 
maximum degradation at 15 minutes and a return to basal levels after 
approximately 30 minutes (Figure 8). As for kB-p we observed no degradation 
for any treatments or time points.
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Effects of split number on cellular responses 
During our research we observed that stimulation agents had dissimilar 
effects on cells from different split numbers. We determined that the older cells 
which were split in excess of 38 times became less responsive to treatments 
than that of the newer lower split numbers. We have established that TNF-a and 
IL-ip have an effect on IkB-o degradation as early as 5 minutes followed by 
maximum degradation at 15 minutes. Experiments carried out together involving 
cells of a higher split number and lower split demonstrated that the higher split 
becomes less responsive at 5 and 15 minutes than that of the lower split (Figure 
9).
Effects of TNF-a and IL-ip on p38, kB-a and kB-p 
at 2-10 minutes
During our studies we hypothesized that the release of IL-6 induced by both 
cytokines in combination may be a result of an enhanced effect on p38 activation 
or kB-a degradation. We first investigated two time points at 2 and 5 minutes 
and did not observe any enhanced effect on p38 activation or kB-a degradation 
at 2 minutes (Figure 10). At 5 minutes both cytokines combined appeared to 
have a stronger effect on kB-a degradation than either single cytokine 
treatments alone. Additional time points at 7.5 and 10 minutes were further 
analyzed (Figure 11). At 7.5 minutes there is more kB-a degradation when 
treated with both cytokines and at 10 minutes we see considerably more
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degradation of IkB-o when treated with both cytokines. There appeared to be no 
enhanced effect on p38 activation at any time points.
Effects of muscimol, baclofen, TNF-a and IL-1P 
on p38, IkB-o and kB-p 
With the effects of muscimol, baclofen, TNF-a and IL-ip on IL-6 characterized 
in an ELISA format we then explored the effects each had on p38, kB-a and kB- 
P using Western blots (Figure 12). At the maximum doses of 100 ng/mL for TNF- 
a and 50 ng/mL IL-ip we observed activation of p38 and degradation of kB-a 
but not kB-p when treated with cytokines alone or in combination. In addition, 
muscimol and baclofen did not reverse the effects of the cytokines when used in 
combination.
Effects of TNF-a, IL-ip, BAY 11-7082 and GABA 
on kB-a degradation 
We determined the effects TNF-a, IL-ip, Bay 11-7082 and GABA on kB-a 
degradation via Western blot. Bay 11-7082 (Figure 13) is an inhibitor of NF-kB 
and prevents the phosphorylation of inhibitory protein inhibitor-xB-p (kB-P) 
bound to NF-kB (Ohkita et al., 2002), in addition it can also inhibit kB-p 
expression (Lappas et al., 2005). We observed a considerable increase in 
degradation kB-a when cells were treated with 100 ng/mL TNF-a, 50 ng/mL IL- 
ip  alone and with both cytokines combined (Figure 14) which was reversed by
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Bay 11-7082. In addition the inhibitory peptide GABA had no effect in reversing 
this degradation.
Effects of low concentrations of TNF-a and IL-1 p 
on p38, IkB-o and kB-p 
We previously characterized the effects TNF-a and IL-ip have on p38, kB-a 
and kB-p (data not shown). Although both cytokines are effective at higher 
concentrations it was necessary to characterize the effects of these cytokines at 
lower concentrations to determine a minimum effective concentration. We first 
analyzed 1 ng/mL TNF-a at three different concentrations of IL-ip that included 
0.5,1 and 5 ng/mL. For the TNF-a treatment alone we observed little or no effect 
on p38 activation and virtually no effect on kB-a or kB-p degradation (Figure 
15). We observed little or no effect on p38 activation, kB-a or kB-p degradation 
when treated with IL-ip at 0.5 ng/mL. At 1 ng/mL we observed a weak activation 
of p38 when compared to the 0.5 ng/mL treatment and an increased activation 
when treated with 5 ng/mL of both cytokines. This p38 activation coincided with a 
strong degradation of kB-a. In addition there was no effect on kB-p degradation 
for any treatment groups.
Effects of low concentrations of TNF-a, IL-1 P and GABA 
on kB-a and kB-p
With the effects of low concentrations cytokines characterized we opted to 
increase these concentrations of TNF-a and IL-ip in an attempt to clarify a more
25
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observable effect on IkB-q and kB-p, for this we used concentrations of 2, 5 and 
10 ng/mL for both TNF-a and IL-ip. Consistent with previous findings the co­
treatments of both cytokines caused the degradation of the NF-kB Inhibitors kB- 
a but not kB-p. Furthermore, ImM GABA did not reverse this effect (Figure 16).
Effects of TNF-a, IL-1 p and GABA dose responses 
on kB-a and kB-p
With low cytokines concentrations characterized we decided to use 2 ng/mL 
as our low effective concentration. Furthermore, in conjunction with the cytokine 
co-treatments we characterized a GABA dose response ranging in concentration 
from 0.01 to 10 mM. As expected, co-treatments of both cytokines caused the 
degradation of the NF-kB inhibitors kB-a but not kB-p. In addition con- 
treatments caused the activation of p38 (Figure 17). Furthermore, GABA 
treatments did not reverse the effects of the cytokines.
Effects of TNF-a, IL-1 P and GABA on IL-6 transcription 
Next, we evaluated the effects of TNF-a, IL-ip and GABA on IL-6 
transcription. TNF-a and IL-ip caused an increase in IL-6 transcription (Figure 
18), in addition both cytokines combined induced a large increase in IL-6 
transcription. Interestingly, when cytokines and GABA are combined, GABA did 
not inhibit IL-6 transcription induced by both cytokines. Relative expression levels 
were measured verifying visual observations (Figure 19).
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Evaluation of total cellular content of IL-6 
We have demonstrated that we can measure IL-6 release through the use of 
ELISA. We explored the idea of assaying total cellular IL-6 content via Western 
blot. We evaluated three different rabbit anti-rat IL-6 antibodies purchased from 
Pierce Biotechnology, Peprotech and Cell Sciences (Figure 20). The antibody 
purchased from Cell Sciences demonstrated more specific binding to IL-6 
allowing us to better distinguish IL-6. In addition when 25 pg of protein were 
loaded into each well the bands were clearly more intense than that of the other 
antibodies. With these results further IL-6 Western analysis was done using the 
Cell Sciences antibody and based on the intensity of the bands a lower amount 
of protein was analyzed. We analyzed 10 pg of protein separated on Western 
blot to determine the effects of GABA and cytokines (Figure 21). We observed a 
more intense IL-6 band for the TNF-a and IL-ip combined treatment indicating a 
large amount of IL-6. This accumulation of IL-6 was reversed with the use of 
GABA.
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CHAPTER 4
DISCUSSION 
GABA inhibition of the synergistic release 
of IL-6 by TNF-a and IL-1P 
Our lab has previously established that TNF-a and IL-ip combined induce a 
synergistic effect on IL-6 release (data not shown). To evaluate the roles of 
GABA and agonists on IL-6 release, it was necessary to characterize IL-6 
release induced by these two cytokines in a time dependent manner (Figure 5). 
After 4 hours of treatment no detectable amounts of IL-6 was released. 
Detectable levels of IL-6 occurred at approximately 6 hours, continuing after 8 
hours with maximum accumulation of IL-6 after 24 hours.
We have previously reported that GABA can inhibit the release of IL-6 
induced by IL-1P treatment (Spangelo et al., 2004) using the 7TD-1 bioassay. 
These observations were re-explored in an ELISA format from 6-12 hours 
(Figure 6). We found that GABA can inhibit IL-6 release at all time points 
supporting our previous findings. We then examined the effects of GABA 
muscimol, baclofen TNF-a and IL-ip on IL-6 release and found that GABA, 
muscimol and baclofen were all able to inhibit the synergistic stimulation of IL-6 
release induced by TNF-a and IL-ip (Figure 7). This preliminary data suggests
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that GABA inhibition of IL-6 can use either GABA receptor subtypes for signaling. 
We determined through a literature search that 100 pM of baclofen is the 
standard concentration used, whereas we used 500 pM. We will reevaluate these 
results using the recommended dose of 100 pM baclofen and we predict that 
GABA and muscimol but not baclofen will inhibit IL-6 release caused by Tl 
synergy.
Mechanism of the TNF-a and IL-ip synergistic stimulation
of IL-6 release
Our first hypothesis states that the synergistic effect of TNF-a and IL-ip on 
IL-6 release is caused by an increase in IL-6 transcription. In order to test this we 
felt it was necessary to first characterize the kinetics of TNF-a and IL-ip on p38 
activation and IkB degradation. We see that both cytokines used together 
activated p38 at approximately 5 minutes reaching maximum activation at 15 
minutes followed by a return to basal activity after 30 minutes (Figure 8). 
Coincidentally there is considerable degradation in kB-a starting at 
approximately 5 minutes with maximum degradation occurring at 15 minutes and 
a return to basal activity at 30 minutes. Consistent with previous experiments we 
observed no changes in kB-p degradation.
During our research we observed that stimulatory agents were having 
dissimilar effects on cell lines of different split numbers. It appeared that the 
higher split numbers starting at approximately 38 become less responsive to our 
treatments. We tested this observation on the two different split lines with
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cytokines alone and in combination and we determined that the high split 
numbers become less responsive. We have established that cytokine treatments 
induce IkB-o degradation as early as 5 minutes followed by maximum 
degradation at 15 minutes. Experiments carried out together involving the two 
different split numbers demonstrated that the higher split number did not respond 
to our treatments at either 5 or 15 minutes (Figure 9). From these observations 
we determined that cell cultures of approximately 38 splits were to be discarded 
and fresh cell cultures grown to replace them. After these observations all 
subsequent experiments were done with cell splits of 5-35.
In regards to the previous kinetics study we postulated that the synergistic 
effect of IL-6 transcription and subsequent release may be a result of an 
accelerated effect on p38 activation and/or NF-kB activation. We have 
established that p38 activation and IkB-o degradation occur as early as 5 
minutes when cytokines are used alone. We predicted that if there is an 
accelerated effect when both cytokines are used together we would observe 
activation of p38 or IkB-o degradation at earlier time points or a stronger 
activation. We decided the first time points to be examined would be 2 and 5 
minutes (Figure 10). For the 2 minute time point we did not observe any effect 
on p38 activation or IkB-q degradation. However, when both cytokines are 
combined there appears to be a increase in p38 activation and IkB-o degradation 
at 5 minutes when compared to cytokines alone. From this observation we then 
decided to analyze the effects of both cytokines at further time points of 7.5 and 
10 minutes (Figure 11). Consistent with our previous findings, groups treated
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with cytokines alone had an increase in activated p38 and IkB-o degradation. 
When compared to groups treated with both cytokines, we observed a stronger 
activation of p38 and degradation of IkB-o for all time points. From this data 
presented we propose that the synergistic induction of IL-6 release caused by the 
combined effects of TNF-a and IL-1P is a result of an accelerated effect on p38 
and NF-kB activation.
Effects of GABA on the inhibition of IL-6 release induced 
by TNF-a and IL-1P 
With guidance from our ELISA data we then explored the effects of each 
cytokines alone, together and in combination with muscimol or baclofen. This 
was done to determine how each affected p38 activation, IkB-o and IkB-P 
degradation in an attempt to determine if the signaling goes through one of these 
modes. At the maximum doses of 100 ng/mL for TNF-a and 50 ng/mL IL-ip we 
observed activation of p38 and degradation of IkB-o but not kB-p when treated 
with cytokines alone or in combination (Figure 12). In addition, muscimol and 
baclofen did not reverse the effects of the cytokines when used in combination.
Our previous findings have shown that Bay 11-7082 can inhibit the 
synergistically stimulated release of IL-6 (data not shown). With this in mind we 
used this NF-kB inhibitor as a positive control for GABA. We observed a 
considerable increase in degradation kB-a when 100 ng/mL TNF-a, 50 ng/mL 
IL-ip and with both cytokines combined (Figure 14). In addition the NF-kB 
inhibitor Bay 11-7082 effectively inhibited the degradation of kB-a but GABA had
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no effect in reversing this degradation. From our ELISA data and Western data 
we concluded that GABA, muscimol and baclofen had no inhibitory effect on p38 
activation or IkB degradation.
Using maximum doses of cytokines, GABA and agonists resulted in no 
observable effects on p38 activation and IkB degradation. We postulated that the 
effects of GABA and agonists may be subtle and thus masked by a high effective 
concentration of both cytokines. Therefore, we designed a series of experiments 
to determine the minimum effective concentration of these cytokines that induces 
a minimal response to p38 activation and IkB degradation. Once a concentration 
of minimal effect was determined we would then use cytokines at this low 
concentration treat and co-treat with the maximal dose of GABA in an attempt to 
induce a stronger response from GABA that should not be masked by the 
cytokines at minimal doses.
To determine the minimal effective dose we started at 1 ng/mL TNF-a and 
compared this to three different doses of IL-13 that included 0.5, 1 and 5 ng/mL 
(Figure 15). For the TNF-a treatments we observed little or no effect on p38 
activation and virtually no effect on kB-a or kB-p degradation. Treatment with 
IL-ip of 0.5 ng/mL the effects were similar to TNF-a and there was little effect on 
p38 activation and no degradation on either kB. At 1 ng/mL we observed a 
stronger activation of p38 when compared to the 0.5 ng/mL and no degradation 
in kB-a and no change in kB-p. When treated 5 ng/mL IL-ip we observed 
stronger activation of p38 and degradation of kB-a than those compared to the 
other doses and 1 ng/mL TNF-a. When combined with 1 ng/mL TNF-a we find
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that TNF-a and 0.5 ng/ mL IL-ip had little or no effect on p38 activation and 
virtually no effect on degradation on either IkB. When treated with 1 ng/mL TNF- 
a and 1 ng/mL IL-ip we find a weak activation of p38 and some degradation in 
IkB-o and this effect is even more obvious when 1 ng/mL TNF-a is combined with 
5 ng/mL IL-1 p.
With a minimum effective dose determined for both cytokines we decided to 
further explore the effects of minimal concentrations. We decided to analyze the 
effects of equal amounts of cytokines and analyzed the effects of 2, 5 and 10 
ng/mL (Figure 16). For these treatments we observed degradation of kB-a but 
no change in kB-p degradation. However, the effects were weaker for the 2 and 
5 ng/mL treatment groups when compared to the 10 ng/mL group. From these 
results we decided to use 2 ng/mL concentrations combined with GABA. The 
concentrations of GABA for this treatment included 0.01, 0.1, 1 and 10 mM. We 
observed no effect in p38 activation or kB-p degradation from any treatment 
groups for cytokines alone or in combination with GABA (Figure 17). With these 
results it has been demonstrated that GABA did not inhibit p38 activation or kB-a 
degradation at both low and high doses. All the results presented to this point 
effectively refuted our second hypothesis that GABA may have an effect on p38 
and NF-kB activation.
With one hypothesis refuted we then analyzed the effects of IL-6 transcription 
which is the basis of our other two hypotheses. We observed that treatment with 
100 ng/mL TNF-a or 50 ng/mL IL-ip resulted in increase of IL-6 transcription 
(Figure 18 and 19). When both cytokines used in combination a massive
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induction of IL-6 occurs, this induction was not simply an additive effect of either 
cytokine but several times greater (synergistic). This result provides evidence 
that supports our first hypothesis that states the synergistic effect of TNF-a and 
IL-ip may act on IL-6 transcription. We have demonstrated that when both 
cytokines are used in combination there is an accelerated effect on p38 
activation and kB-a degradation. Combined with this result we propose that this 
synergistic effect is a result of the combined cytokines having accelerated effects 
on p38 activation and NF-kB activation ultimately resulting in an accelerated 
increase in IL-6 transcription. Furthermore, we hypothesized that GABA may 
inhibit this synergistic effect by inhibiting IL-6 transcription. If true, we predict that 
we would see a decrease in IL-6 transcripts when treated with GABA. However, 
we observed that GABA did not inhibit IL-6 transcription caused by both 
cytokines combined. This is in opposition to our prediction and suggests that 
GABA contributes to an increase of IL-6 or even stabilizes the transcript. We 
argue that there is an accumulation in IL-6 transcript in the GABA treated groups 
because GABA may prevent the translation of IL-6.
From the mRNA data we hypothesized that GABA may be preventing the 
translation of IL-6. With this in mind we predicted that if GABA prevents IL-6 
translation we will see a decrease in IL-6 content in GABA treated groups when 
analyzed via Western blot. In order to test this we first had to determine if a 
Western format is feasible for IL-6 analysis. For this experiment C6 cells were 
plated, no stimulation agents were used and protein extracted (Figure 20). We 
analyzed these blots with an anti-rat IL-6 antibody (1:1000 dilution) purchased
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from Pierce Biotechnology, Peprotech and Cell Sciences. For all antibodies we 
were able to detect IL-6 and also observed non-specific binding at other weight 
ranges. The antibodies purchased from Pierce and Peprotech were very similar, 
the antibody purchased from Cell Sciences gave us the best results. We 
determined an effective detection by two categories [a] a limit on non-specific 
binding and [b] the intensity of the bands/signal at the 28 kDa range where 
functional IL-6 should be isolated. With the Cell Sciences antibody there was 
more specific binding and a stronger signal detected at the 28 kDa range. Also 
we concluded that the band was too intense and may be indicative of protein 
overloading. Therefore for future IL-6 Westerns we lowered the amount of protein 
to load from 25 pg to 10 pg. With these results we concluded that it is possible to 
measure IL-6 effectively in a Western format and that the Cell Sciences antibody 
proved to be the ideal reagent.
We then analyzed the effect of GABA and cytokines on IL-6 content (Figure 
21). We observed a large accumulation of IL-6 for the TNF-a and IL-ip combined 
treatments and when these two were combined with GABA less IL-6 was 
detected. This result combined with the mRNA data suggests that GABA 
inhibition of IL-6 release may act through the prevention of IL-6 translation. This 
possibility will be explored in future endeavors by our lab. From these results we 
ruled out our third hypothesis that GABA inhibits IL-6 transcription but determined 
that GABA appears to inhibit IL-6 translation. With the information gathered for 
this thesis we have proposed a potential GABA inhibitory pathway shown in 
Figure 22.
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A potential model for GABA inhibition of IL-6 translation may be through the 
activation of 4E-BP1 also known as PHAS 1. In eukaryotes, mRNA posses a 5’ 
“cap” structure which is recognized by the cap binding protein elF4E allowing the 
first step in ribosome scanning (Martin et al., 2000). Different stimuli can cause 
the phosphorylation of elF4E, which activates this initiation factor resulting in an 
increase in protein synthesis (Sonenberg 1996). In addition the activation of 
elF4E enhances its affinity to bind to mRNA (Minich et al., 1994). 4E-BP1 is a 
cytoplasmic inhibitor which maintains elF4E in an inactive form (Martin et al., 
2000). Phosphorylation of 4E-BP1 causes it to release elF4E allowing the proper 
formation of a functional elF4E complex that allows efficient binging and proper 
positioning of the 40 S ribosomal subunit on mRNA (Lawrence and Abraham 
1997).
GABA may be preventing 4E-BP1 from releasing elF4E, preventing the 
ribosomal complex from forming in turn inhibiting translation. Interestingly, a 
functional assay for 4E-BP-elF4E binding was developed by Gingras and 
colleagues from which we could test the effects of GABA. Using this method we 
predict that TNF-a and IL-ip combined treatments will result in the dissociation of 
4E-BP-elF4E complex which will be inhibited by GABA.
Polysome fractionation is another potential method to assay for translational 
inhibition in a method similar to that described by Koritzinsky and colleagues. 
This method involves the separation of cell lysates on sucrose gradients then 
RNA levels are measured as a function of gradient depth. Efficient translation of 
mRNA requires the association with many ribosomes (polysomes) and therefore
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would sediment deep in the sucrose gradients (Koritzinsky et al., 2005). We 
hypothesize that GABA may inhibit translation by preventing the formation of the 
polysomes. We predict that TNF-a and IL-1P combined treatments will result in 
polysomal bands deep in the sucrose gradients. Furthermore, we predict that this 
banding deep in the sucrose gradient will not be present in the GABA treated 
groups.
In summary, from the results presented in this thesis we have evidence 
suggesting that the synergistic effect of TNF-a and IL-ip is a result of an 
enhanced effect on p38 and NF-kB activation resulting in enhanced IL-6 
transcription. Furthermore, GABA may prevent IL-6 translation based on the 
following three observations, [a] GABA did not prevent the activation of p38 and 
or NF-kB, [b] GABA did not reduce the transcription of IL-6 and [c] GABA treated 
groups had less total cellular IL-6. From this data we postulate that this decrease 
of IL-6 protein is a result of GABA inhibiting translation possibly by blocking IL-6 
transcript release from the nucleus or by inhibiting translation directly.
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Figure 1 : Representation demonstrating that neuroinflammation and beta 
amyloid synergy is essential to AD progression
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Figure 2: Structural projection for the inhibitory neurotransmitter GABA.
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Figure 3: Structural projections of GABA receptor agonists. Muscimol acts on 
GABAa receptors and baclofen on GABAb receptors.
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Figure 4: GABA inhibition of the synergistic release of IL-6 by IL-1p and TNF- 
a. Rat C6 cells were plated (1.0 x 10® cells/well in a PDL-coated 24-well 
plate) and were pretreated with 1 mM GABA for 1 hour and co-treated with 1 
mM GABA, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 20 hours. Post 
stimulation, conditioned medium was removed and assayed for IL-6 using 
Pierce ELISA according to the manufacturer’s specifications. A (+) indicates 
C6 glioma cells were treated as; con = no stimulation agents T = TNF-a, I = 
IL-ip, G = GABA. Data presented in this figure is a confirmation of previous 
unpublished results. The data are presented as mean ± s.e.m. of triplicates 
observations obtained from a single representative experiment.
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Figure 5: Time dependent release of IL-6 by IL-ip and TNF-a. Rat C6 cells 
were plated (1.0x10® cells/well in a PDL-coated 24-well plate) treated with 50 
ng/mL IL-ip and 100 ng/mL TNF-a alone or in combination for 4, 6 ,8 ,12  and 
24 hours. Post stimulation, conditioned medium was removed and assayed 
for IL-6 using Pierce ELISA according to the manufacturer’s specifications. 
C6 glioma cells were treated as; C = no stimulation agents Tl = TNF-a and IL- 
1 combined with times indicated by hrs = hours. The data are presented as 
mean ± s.e.m. of triplicates observations obtained from a single 
representative experiment.
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Figure 6: GABA inhibition of the synergistic release of IL-6 by IL-ip and TNF-a. 
Rat C6 cells were plated (125 x 10® cells/well in a PDL-coated 96-well plate) and 
were pretreated with 1 mM GABA alone for 1 hour and co-treated with 50 ng/mL 
IL-ip and 100 ng/mL TNF-a for 4-12 hours. Post stimulation, conditioned 
medium was removed and assayed for IL-6 using Pierce ELISA according to the 
manufacturer’s specifications. T = TNF-a, I = IL-ip and G = GABA. The data are 
presented as mean ± s.e.m. of triplicate observations obtained from a single 
representative experiment.
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Figure 7: GABA inhibition of the synergistic release of IL-6 by IL-ip and TNF- 
a. Rat 06  cells were plated (125 x 10® cells/well in a PDL-coated 96-well 
plate) and were pretreated with inhibitors (1 mM GABA, 100 |iM muscimol 
and 500 pM baclofen) alone for 1 hour and co-treated with inhibitors alone, 50 
ng/mL IL-ip and 100 ng/mL TNF-a for 20 hours. Post stimulation, conditioned 
medium was removed and assayed for IL-6 using Pierce ELISA according to 
the manufacturer’s specifications. T = TNF-a, I = IL-ip, G = GABA, M = 
muscimol and B = baclofen. The data are presented as mean ± s.e.m. of 
triplicate observations obtained from a single representative experiment.
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Figure 8: The extended time course and effects of TNF-a and IL-1P on p38 
activation and degradation of IxB-a and IxB-p. Rat C6 cells (3x10® cells/dish 
in a 35 X 10 mm-dish) were treated 50 ng/mL IL-ip and 100 ng/mL TNF-a for 
0, 5, 15, 30, 45, 60, 90 and 120 minutes. Post stimulation, cellular protein 
was extracted, and 25 pg of total protein were subsequently separated via 
SDS-PAGE followed by Western analysis for IxB-a, IkB-P, phosphorylated or 
total p38 protein (1:1000 for all). The data are presented as the observations 
obtained from a single experiment.
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Figure 9: The effects of TNF-a and IL-ip degradation of kB -a and IkB-P for 
high and low cell splits. Rat C6 cells (3x10® cells/dish in a 35 x 10 mm-dish) 
were treated 50 ng/mL IL-ip and 100 ng/mL TNF-a for 0, 5, 15, 30, 45, 60, 90 
and 120 minutes. Post-stimulation, cellular protein was extracted, and 25 pg 
of total protein were subsequently separated via SDS-PAGE followed by 
Western analysis for kB-a, kB-p, phosphorylated or total p38 protein (1:1000 
for all). The data are presented as the observations obtained from a single 
experiment.
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Figure 10: The effects of TNF-a and IL-ip on p38 activation and degradation 
of kB -a and kB-p at 2 and 5 minute time points. Rat C6 cells (3 x 10® 
cells/dish in a 35 x 10 mm-dish) were treated 50 ng/mL IL-ip and 100 ng/mL 
TNF-a for 2 and 5 minutes. Post stimulation, cellular protein was extracted, 
and 25 pg of total protein were subsequently separated via SDS-PAGE 
followed by Western analysis for kB-a, kB-p, phosphorylated or total p38 
protein (1:1000 for all). The data are presented as the observations obtained 
from a single experiment.
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Figure 11: The effects of TNF-a and IL-ip on p38 activation and degradation 
of kB -a and kB-p at 5, 7.5 and 10 minute time points. Rat C6 cells (3x10® 
cells/dish in a 35 x 10 mm-dish) were treated 50 ng/mL IL-ip and 100 ng/mL 
TNF-a for 5, 7.5 and 10 minutes. Post stimulation, cellular protein was 
extracted, and 25 pg of total protein were subsequently separated via SDS- 
PAGE followed by Western analysis for kB-a, kB-p, phosphorylated or total 
p38 protein (1:1000 for all). The data are presented as the observations 
obtained from a single experiment.
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Figure 12: The effects of muscimol and baclofen on p38, kB -a and kB-p. 
Rat C6 cells (3x10® cells/dish in a 35 x 10 mm-dish) were pre-treated with 
100 pM muscimol or 100 pM baclofen for 1 hour, and co-treated with either 
100 pM muscimol or 100 pM baclofen, 50 ng/mL IL-ip and 100 ng/mL TNF-a 
for 15 min. Post stimulation, cellular protein was extracted, and 25 pg of total 
protein were subsequently separated via SDS-PAGE followed by Western 
analysis for kB-a, kB-p, phosphorylated or total p38 protein (1:1000 for all). 
The data are presented as the observations obtained from a single 
experiment.
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Figure 13: Structural projections of BAY 11-7082 which inhibits NF-kappaB by 
preventing the phosphorylation of kB-p bound to NF-kB.
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Figure 14: The effect of Bay 11-7082 on the degradation of kB-a. Rat C6 
cells (3x10® cells/dish in a 35 x 10 mm-dish) were pre-treated with 25 pM 
Bay 11-7082 for 1 hour, and co-treated with 25 pM Bay 11-7082, 50 ng/mL IL- 
ip  and 100 ng/mL TNF-a for 15 min. Post stimulation, cellular protein was 
extracted, and 25 pg of total protein were subsequently separated via SDS- 
PAGE followed by Western analysis for kB protein (1:1000). The data are 
presented as the observations obtained from a single experiment.
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Figure 15: The effects of low concentrations on cytokine on p38 activation 
and the degradation of kB -a and kB-p. Rat C6 cells (3x10® cells/dish in a 
35 X 10 mm-dish) were treated 0.5, 1 and 5 ng/mL IL-ip and Ing/mL TNF-a 
for 15 min. Post stimulation, cellular protein was extracted, and 25 pg of total 
protein were subsequently separated via SDS-PAGE followed by Western 
analysis for kB-a, kB-p, phosphorylated or total p38 protein (1:1000 for all). 
The data are presented as the observations obtained from a single 
experiment.
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Figure 16: The effects of low concentrations of cytokine on p38 activation and 
the degradation of kB -a and kB-p. Rat C6 cells (3x10® cells/dish in a 35 x 
10 mm-dish) were treated 2, 5 and 10 ng/mL IL-ip and TNF-a for 15 min. 
Post stimulation, cellular protein was extracted, and 25 pg of total protein 
were subsequently separated via SDS-PAGE followed by Western analysis 
for kB -a and kB  (1:1000 for both). The data are presented as the 
observations obtained from a single experiment.
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Figure 17: The effects of low concentrations of cytokine and GABA on p38 
activation and the degradation of kB -a and kB-p. Rat 06  cells (3 x 10® 
cells/dish in a 35 x 10 mm-dish) were pre-treated with 0.01, 0.1, 1 and 10 mM 
GABA for 1 hour, and co-treated with either 0.01, 0.1, 1 and 10 mM GABA, 2 
ng/mL IL-ip and 2 ng/mL TNF-a for 15 min. Post stimulation, cellular protein 
was extracted, and 25 pg of total protein were subsequently separated via 
SDS-PAGE followed by Western analysis for kB-a, kB-p, phosphorylated or 
total p38 protein (1:1000 for all). The data are presented as the observations 
obtained from a single experiment.
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Figure 18: Relative expression of IL-6 transcript in cells treated with GABA, 
TNF-a and IL-ip. Rat C6 cells (3x10® cells/dish in a 35 x 10 mm-dish) were 
pre-treated with 1 mM GABA for 1 hour, and co-treated with either 1 mM 
GABA, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 4 hours. Post stimulation, 
cellular RNA was extracted, and 1 pg of total RNA extract were subsequently 
separated and analyzed via semi-quantitative RT-PCR. The data are 
presented as the observations obtained from a single experiment.
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Figure 19: Relative expression of IL-6 transcript in cells treated with GABA, 
TNF-a and IL-1|3. Rat C6 cells (3x10® cells/dish in a 35 x 10 mm-dish) were 
pre-treated with 1 mM GABA for 1 hour, and co-treated with either 1 mM 
GABA, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 4 hours. Post stimulation, 
cellular RNA was extracted, and 1 |ig of total RNA extract were subsequently 
separated and analyzed via semi-quantitative RT-PCR for IL-6 transcript 
relative expression levels determined. The data are presented as the 
observations obtained from four experiments.
56
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Pierce Peprotech Cell Sciences
IL-6
Figure 20: Relative effectiveness of IL-6 antibody from Pierce Biotechnology, 
Peprotech and Cell Sciences. Rat C6 cells (3x10® cells/dish in a 35 x 10 
mm-dish). Cellular protein was extracted, and 25 pg of total protein were 
subsequently separated via SDS-PAGE followed by Western analysis using 
antibodies from each manufacturer (1:1000 for all). The data are presented as 
the observations obtained from a single experiment.
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Figure 21: IL-6 content of TNF-a and IL-ip on p38 activation and degradation 
of lK0-a and kB-p. Rat C6 cells (3 x 10® cells/dish in a 35 x 10 mm-dish) 
were treated 50 ng/mL IL-ip, 100 ng/mL TNF-a and 1 mM GABA alone or in 
combination 4 hours. Post stimulation, cellular protein was extracted, and 25 
pg of total protein were subsequently separated via SDS-PAGE followed by 
Western analysis for kB-a, kB-p, phosphorylated or total p38 protein (1:1000 
for all). The data are presented as the observations obtained from a single 
experiment.
58
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
IL-ip TNF-a
p 3 8 I K K
i
NFk B- Ik B
I L - 6  t r a n s c r i p t i o n
ic
I L - 6  t r a n s l a t i o n
Transcript shuttling from 
nucieus GABA
Figure 22: Proposed mechanism of GABA inhibition of IL-6 release caused by 
the synergistic induction of TNF-a and IL-ip.
59
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
REFERENCES
Abraham E (2000) NF-kappa B activation. Crit. Care. Med. 28(4 SuppI): N100-4.
Alzheimer, A. (1907) Uber eine eigenartige Erkangkung der Hirnrinde. [An 
unusual illness of the cerebral cortex.] Allgemeine Zeitschr Psychisch- 
Gerichtliche Medizin. 64: 146-8 [in German].
Avila J (2006) Tau phosphorylation and aggregation in Alzheimer’s disease 
pathology. FEBS Lett. 580:2922-2927.
Banks Ml, Hardie JB, Pearce RA (2002) Development of GABA(A) receptor- 
mediated inhibitory postsynaptic currents in hippocampus. J. Neurophysiol. 
88(6): 3097-3107.
Bareggi SR, Franceschi M, Bonini L, Zecca L, Smirne 8 (1982) Decreased CSF 
concentrations of honovanillic acid and y-aminobutyric acid in Alzheimer’s 
disease. Arch. Neurol. 39: 709-712.
Bell 8, Matthews JR, Jaffray E, Hay RT (1996) l(kappa)B(gamma) inhibits DNA 
binding of NF-kappaB p50 homodimers by interacting with residues that contact 
DNA. Mol. Cell. Biol. 16(11): 6477-6485.
Best KL and Mason MJ (1995) Thapsigargin and cyclopiazonic acid initiate rapid 
and dramatic increases of IL-6 mRNA expression and IL-6 secretion in murine 
peritoneal macrophages. J Immunio. 155: 285-296
Bowsher D (1988) Basic Cellular Elements and Development of the Central 
Nervous 8ystem, in D. Bowsher (Ed), Introduction to the Anatomy and 
Physiology of the Nervous 8ystem, Blackwell 8cientific Publications, Oxford, pp 
4-18
Braak H, Braak E, 8trothjohann M. (1994) Abnormally phosphorylated tau protein 
related to the formation of neurofibrillary tangles and neuropil threads in the 
cerebral cortex of sheep and goat. Neurosci Lett. 171: 1-4.
Braak H, Braak E, 8trothjohann M. (1994) Abnormally phosphorylated tau protein 
related to the formation of neurofibrillary tangles and neuropil threads in the 
cerebral cortex of sheep and goat. Neurosci Lett. 171: 1-4.
60
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Buxbaum JD, Thinakaran G, Koliatsos V, O’Callahan J, Slunt HH, Price DL, 
Sisodia SS (1998) Alzheimer amyloid protein precursor in the rat hippocampus: 
Transport and processing through the perforant pathway. J Neurosci. 18: 9629- 
9237.
Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, 
Greengard P. (1992) Cholinergic agonists and interleukin 1 regulate processing 
and secretion of the Alzheimer beta/A4amyloid protein precursos. Proc. Natl. 
Acad. Sci. USA. 89: 10075-10078.
Caceres A, Kosik KS (1990) Inhibition of neurite polarity by tau antisense 
oligonucleotides in primary cerebellar neurons. Nature 343: 461-463.
Carswell R, Old L, Kassep R, Green N, Fiore N, Williamspm B (1975) An 
Endooxin-induced Serum Factor that causes Necrosis of Tumors. PNAS 72(9): 
3666-3670
Chen Y, Tang BL (2006) The amyloid precursor protein and postnatal 
neurogenesis/neuroregeneration. Biochem. Biophys. Res. Commun. 341: 1-5.
Cintron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad 
B, Venizelos N, Lannfelt L, Selkoe DJ. (1994) Excessive production of amyloid 3- 
protein by peripheral cells of symptomatic and presymptomatic patients carrying 
the Swedish familial Alzheimer disease mutation. Proc. Natl. Acad. Sci. USA. 91: 
11993-11997.
Craig R, Larkin A, Mingo AM, Thuerauf DJ, Andrews C, McDonough PM, 
Glembotski CC. (2000) p38 MAPK and NF-kappa B collaborate to induce 
interlukin-6 gene expression and release. Evidence for a cytoprotective autocrine 
pathway in a cardiac myocyte model system. J. Bid. Chem. 275(31): 23814- 
23824.
Davis N, Ghosh S, Simmons DL, Tempst L, Liou HC, Baltimore D, Bose HRJ 
(1991) Rel-associated pp40:an inhibitor of the Rel family of transcription factors. 
Science 253: 1268-1271
Dewitt DA, Cohen PM, Doller C, Silver J. (1998) Astrocytes regulate microglial 
phagocytosis of senile plaque cores of Alzheimer’s disease. Exp Neurol. 149: 
329-340.
Dinarello CA. (1994) The interleukin-1 family: 10 years of discovery. The FASEB 
Journal. 8: 1314-1325.
Drubin DG, Kirschner MW (1986) Tau protein functioning in living cells. J. Cell. 
Biol. 103: 2739-2746.
61
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Ebneth A, Godemann R, Stamer K, lllenberger S, Trinczel B, Mandelkow E. 
(1998) Overexpression of tau protein inhibits kinesin-dependent trafficking of 
vesicles, mitochondria, and endoplasmic reticulum: implication for Alzheimer’s 
disease. J Cell Biol. 143(2): 777-794.
Elsawa SF and Bost KL (2004) Murine gamma-herpesvirus-68-induced IL-12 
contributes to the control of latent viral burden, but also contributes to viral- 
mediated leukocytosis. J Immunol. 172: 516-524
Eynott PR, Nath P, Leung SY, Adcock IM, Bennett BL, Chung KF. (2003) 
Allergen-induced inflammation and airway epithelial and smooth muscle cell 
proliferation: role of Jun N-terminal kinase. Br. J. Pharmacie. 140(8): 1373-1380.
Federici M, Geracitano R, Tozzi A, Longone P, Di Angelantonio S, Bengston CP, 
Bernardi G, Mercuru NB (2005) Trace Amines Depress GABAb Response in 
Dopaminergic Neurons by Inhibiting G-Py-Gated Inwardly Rectifying Potassium 
Channels. Mol. Pharmacol. 67: 1283-1290
Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, 
Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, 
Scazufca M (2005) Global Prevelance of Demetia: a Delphi Consensus Study. 
Lancet 366: 2112-2117.
Gentlemen SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW (1993) Beta- 
amyloid precursor protein as a marker for axonal injury after head injury. 
Neurosci. Lett. 160. 139-144.
Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Steven Jacobsen J, 
Vitek MP, Carleton Gajdusek D. (1989) Interleukin 1 Regulates Synthesis of 
Amyloid p -protein Precursor in mRNA in Human Endothelial Cells. Proc. Natl. 
Acad. Sci. USA. 86: 7606-7610.
Frolund B, Jeppesen L, Krogsgaard-Larsen P, Hansen JJ (1995) GABAA 
agonists: resolution and pharmacology of (+)- and (-)- isoguvacine oxide. 
Chirality. 6: 434-438.
Ghosh S, May MJ, Kopp EB (1998) NF-kB AND REL PROTEINS: Evolutionary 
Conserved Mediators of Immune Responses. Annu. Rev. Immunoi. 16: 225-260.
Gingras AC, Kennedy SG, O’Leary MA, Sonenberg N, Hay N (1998) 4E-BP1, a 
repressor of mRNA translation, is phosphorylated and inactivated by the 
Akt(PKB) signaling pathways. Genes Dev. 12: 502-513
Granger GA, Shacks SJ, Williams TW, Kolb WP (1969) Lymphocyte in vitro 
cytotoxicity: specific release of lymphotoxin-like materials from tuberculin- 
sensitive lymphoid cells. Nature 221: 1155-1157
62
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Griffin WST (2006) Inflammation and neurodegenerative diseases. Am. J. Clin. 
Nutr. 83(suppl): 470S-474S.
Han SK, Abraham IM, Herbison AE (2002) Effect of GABA on GnRH Neurons 
Switches from Depolarization to Hyperpolarization at Puberty in the Female 
Mouse. Endocrinology 143(4): 1459-1466.
Hardy JA, Higgins GA (1992) Alzheimer’s disease: The amyloid cascade 
hypothesis. Sc/ence 256: 184-185.
Hazuda DJ, Strickler J, Kueppers F, Simon PL, Young PR. (1990) Processing of 
precursor interleukin 1 beta and inflammatory disease. J. Biol. Chem. 265(11): 
6318-6322.
Herbert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer 
Disease in the US Population: Prevelance Estimates Using the 2000 Census. 
Arch Neurol. 60: 1119-1122.
Ip YT, Davis RJ. (1998) Signal transduction by the c-Jun N-terminal kinase 
(JNK)—from inflammation to development. Curr. Opin. Cell Biol. 10(2): 205-219.
Kang J, Lemaire H-G, Unterbeck A, Salbaum J. M, Masters CL, Grzerschik K-H, 
Multhaup G, Beyreuther K, Müller-Hill B (1987) The precursor of Alzheimer’s 
disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733- 
736.
Kaur J, Woodman RC, Kubes P. (2003) P38 MAPK: critical molecule in thrombin- 
induced NF-KB-dependent leukocyte recruitment. Am J Physiol Heart Circ 
Physiol. 284(4): H I095-1103.
Kerr DIB, Ong J (2001) Metabotropic GABAb receptors: new challenges in drug 
design. Curr. Med. Chem. CNS Agents 1: 27-42
Klein WL, Krafft GA, Finch CE (2001) Targeting small Ap oliomers: the solution to 
the Alzheimer’s disease conundrum? Trends Neurosci. 24: 219-223.
Kolaj M, Bai D, Renaud LP (2004) GABAb Receptor Modulation of Rapid 
Inhibitory and Excitatory Neurotransmission From Subfornical Organ and Other 
Afferents to Median Preoptic Nucleus Neurons. J. Neurophysiol. 9 2 :111-122.
Kopp E, Ghosh S. (1995) NF-kB and rel proteins in innate immunity. Adv. 
Immnunol. 58: 1 -27.
Koritzinksy M, Seigneurie R, Magagnin MG, van den Beucken T, Lambin P, 
Wouters B.G. (2005) The hypoxic proteome is influenced by gene-specific 
changes in mRNA translation. Radiother. Oncol. 76: 177-186
63
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Lappas M, Yee K, Permezel M, Rice GE (2005) Sulfasalazine and BAY 11-7082 
interfere with the nuclear factor-kappa B and kappa B kinase pathway to regulate 
the release of the proinflammatory cytokines from human adipose tissue and 
skeletal muscle in vitro. Endocrinology 1491-1497
Lawrence JC, Abraham RT (1997) PHAS/4E-BPs as regulators of mRNA 
translation and cell proliferation. Trends Biochem. Sci. 22: 345-349
Lee SH, Hannink M (2002) Characterization of the Nuclear Import and Export 
Functions of IkBs. J. Biol. Chem. 277(26): 23358-23366.
Li Y, Liu L, Barger SW, Griffin WST (2003) Interleukin-1 mediates pathological 
effects of microglia on tau phosphorylation and on synaptophysin synthesis in 
cortical neurons through a p38-MAPK pathway. J. Neurosci. 23: 1605-1611.
Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor 
superfamilies: intergrating mammalian biology. Ce//104(4): 487-501
Loftier J, HG (1992) Beta-amyloid precursor protein isoforms in various rat brain 
regions and during brain development. J. Neurochem. 59: 1316-1324.
Martin ME, Perez Ml, Redondo C, Alvarez Ml, Salinas M, Fando JL (2000) $E 
binding protein 1 expression is inversely correlated to the progression of 
gastrointestinal cancers. Int. J. Biochem. Celi Biol. 32(6): 633-642
Murashita H, Tabuchi K, Sakai S, Uemaetomari I, Tsuji S, Hara A (2007) The 
effect of the GABAa agonist muscimol on acoustic injury of the mouse cochlea. 
Neurosci. Lett. 418(1): 18-21.
Minich WB, Balasta ML, Goss DJ, Rhoads RE (1994) Chromatographic 
resolution of in vivo-phosphorylated and nonphosphorylated eukaryotic 
translation initiation factor elF-4E: increased cap affinity of the phosphorylated 
form, Proc. Natl. Acad. Sci. USA 91: 7668-7672
Nagele RG, Wiegel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. (2004) 
Contribution of glial cells to the development of amyloid plaques in Alzheimer’s 
disease. Neurobiol. Aging. 25(5): 663-674.
Ohkita M, Takaoka M, Shiota Y, Nojiri R, Suggi M, Matsumura Y (2002) A 
nuclear factor-kappaB inhibitor BAY 11-7082 suppresses endothelin-1 production 
in cultured vascular endothelial cells. Jpn. J. Pharmacol. 89(1): 81-82
Olsen RW and Tobin AJ (1990) Molecular Biology of GABAA receptors. The 
FASEB Journal. 4: 1469-1480.
64
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
O’Neill LAJ (2000) The Interleukin-1 Receptor/Toll-like Receptor Superfamily: 
Signal Transduction During Inflammation and Host Defense. Sci. STKE. (44): 
RE1.
Otis TS, Mody I (1992) Modulation of decay kinetics and frequency of GABAA 
receptor-mediated spontaneous inhibitory postsynaptic currents in hippocampal 
neurons. Neuroscience. 49(1): 13-32.
Pearson AG, Byrne DTE, MacGibbon GA, Faull RLM, Dragunow. (2006) 
Activated c-Jun is present in Neurofibrillary tangles in Alzheimer’s disease brains. 
Neurosci. Lett. 398: 246-250.
Poppek D, Keck S, Ermak G, Jung T, Stolzing A, Ullrich O, Davies KJ, G rune T. 
(2006) Phosphorylation inhibits turnover of the tau protein by the proteasome: 
influence of RCAN1 and oxidative stress. Biochem J. 400(3): 511-520.
Qiao X, Cummins DJ, Paul SM (2001) Neuroinflammation-induced acceleration 
of amylod deposition in APPV717F transgenic mouse. Eur J Neurosci. 14(3): 
474-482.
Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P. (1998) 
Dendritic cell survival and maturation are regulated by different signaling 
pathways. J. Exp. Med. 188: 2175-2180.
Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW (2002) Activation of c-Jun 
N-Terminal Kinase and p38 in an Alzheimer’s Disease Model is Associated with 
Amyloid Deposition. J. Neurosci. 22: 3376-3385.
Selkoe DJ, Podlisny MB, Joachim CL (1988) Beta-amyloid precursor protein of 
Alzheimer disease occurs as 110- to 135-kilodalton membrane associated 
proteins in neural and non-neural tissues. Proc. Natl. Acad. Sci. USA 85: 7341- 
7345.
Selkoe DJ (1996) Amyloid beta-protein and the genetics of Alzheimer’s disease. 
J. Bid. Chem. 271: 18295-18298.
Sonenberg M (1996) mRNA 5’ Cap-binding protein elF4E and control of cell 
growth, in: J.W.B. Hershey, M.B. Matthews, N. Sonenberg (Eds), Translational 
control. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 245-269
Spangelo BL, Horrell S, Goodwin AL, Shroff S, Jarvis WD (2004) Somatostatin 
and gamma-aminobutyric acid inhibit interleukin-1 ^-stimulated release of 
interleukin-6 from rat c6 glioma cells. Neuroimmunomodulation 332-340.
Spiecker M, Darius H, Liao JK (2000) A Functional Role of IkB-e in Endothelial 
Cell Activation. J. Immnunoi. 164: 3316-3322.
65
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EW (2002) Tau blocks 
traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances 
oxidative stress. J. Cell. Biol. 156: 1051-1063.
Tam WF, Sen R (2001) IkB Family Members Function by Different Mechanisms. 
J. Biol. Chem. 276(11): 7701-7704.
Tammas G, Lorincz A, Simon A, Szabadics J (2003) Identified Sources and 
Targets of Slow inhibition in the Neocortex. Sc/ence 299(5614): 1902-1905
Terry RD (1999) The neuropathology of Alzheimer disease and the structural 
basis of its cognitive alterations, in Alzheimer Disease (Terry RD, Katzman R, 
Bick KL, Sisodia SS eds) pp187-206, Lippincott Williams and Wilkins, New York.
Terry RD (2000) Cell death or synaptic loss in Alzheimer disease. J Neuropathol 
Exp Neurol. 59(12): 1118-1119.
Thompson JE, Phillips RJ, Erdjument-Bromage, Tempst P, Ghosh S (1995) IkB- 
P Regulates the Persistent Response in a Biphasic Activation of NF-kB. Ce//80: 
573-582.
Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL (2004) y-Aminobutyric 
Acid Inhibits T Cell Autoimmunity and the Developmental of Inflammatory 
Responses in a Mouse Type 1 Diabetes Model. J Immunol ^73{8): 5298-5304.
Tracey KJ, Cerami A (1994) TUMOR NECROSIS FACTOR: A Pleiotropic 
Cytokine and Therapuetic Target. Annu. Rev. Med. 45: 491-503
Trinczek B, Ebneth A, Mandelkow E. (1999) Tau regulates the 
attachment/detachment but not the speed of motors in microtubule-dependent 
transport of single vesicles and organelles. J. Cell. Sol. 112: 2355-2367.
Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of 
neuropathological changes and dementia of Alzheimer’s disease in Down’s 
syndrome. Ann. Neurol. 17: 278-282.
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. (1995) Opposing 
effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-
1331.S
66
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
VITA
Graduate College 
University of Nevada, Las Vegas
Joseph Dana Roach Jr.
Home Address:
317 Galveston Street 
Las Vegas, NV 89110
Degree:
Bachelor of Science, Biology, 2002 
University of Nevada, Las Vegas
Publication:
Spangelo BL, Roach JD, Had I F, Damavandy AA, Plieskatt J, Badamchian 
M (2007) THYMOSIN FRACTION-5 POSSESSES ANTIPROLIFERATIVE 
PROPERTIES IN HL-60 HUMAN PROMYELOCYTIC LEUKEMIA CELLS: 
CHARACTERIZATION OF AN ACTIVE PEPTIDE. Ann NY Acad Sci.
Epub ahead of print
Thesis Title:
y-Aminobutyric Acid Inhibition of lnterleukln-6 Release from Astrocytoma 
Cells Is not Dependent on NF-kB  and p38
Thesis Examination Committee:
Chairperson, Bryan L. Spangelo, Ph. D.
Committee Member, Ronald K. Gary, Ph. D.
Committee Member, Spencer M. Steinberg, Ph. D.
Graduate College Representative, Deborah K. Hoshizaki, Ph. D.
67
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
